Guggenheim initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $50 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics management to meet with Piper Sandler
- Avalo Therapeutics management to meet with Cantor Fitzgerald
- De-Risked LOTUS Phase 2 Design and Monthly Dosing Support Reiterated Buy on Avalo Therapeutics
- Avalo Therapeutics Highlights AVTX-009 Progress in HS
- Avalo Therapeutics files $750M mixed securities shelf